The Company’s 2025 financial guidance reflects its evolution to a fully integrated commercial-stage biotechnology company independently ...
Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback